Alx Oncology Holdings Inc (ALXO) Smart Money Holdings (13F, Q2 2026)

ALXO ranks #4676 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ALXO is a disclosed holding of Stephen Schwarzman (Blackstone Group), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

ALXO is a top-conviction position for venBio Partners LLC — at 5.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ALXO belongs to Ra Capital Management, L.p., but the position matters far more to venBio Partners LLC, who has 5.1% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

venBio Partners LLC has added to its ALXO position for two straight quarters, increasing it by $15.7M to reach $26.7M today.

ALXO is up 5.1% today, and institutions have been net buyers of $31.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ALXO reported a net loss of $80.9M over the trailing twelve months.

• Not yet profitable — net loss of $80.9M over the trailing twelve months
• Net income improved year over year, from -$116.6M to -$80.9M
• Operating cash flow was negative, using $84.1M in cash
• Current ratio of 2.07x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.27x equity — within a conventional range